France has long been a European leader in rare diseases, from its scientific research and academic hospitals, through to patient advocacy and regulatory reforms that have encouraged R&D. Its biotech and pharmaceutical industries are now leading the way, discovering the next generation of therapies for patients that are often overlooked.

CDER holds steady with a median time to approval of 11 months, while CBER posts 10.5 month median review time for its largest novel approvals class.

Industry veteran Jeremy Levin, the 2023 winner of the Scrip Awards Lifetime Achievement Award, speaks to In Vivo about what holds back innovation in the biopharma industry, new technologies and commitments needed to protect the future relationship between drug developers and patients.

Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.